What is the Denosumab (usan)?

Denosumab (usan) is , while it's Molecular Formula is C6404H9912N1724O2004S50. Prevention and treatment of all forms of osteoporosis or bone loss.

What is the CAS number for Denosumab (usan)?

The CAS number of Denosumab (usan) is 615258-40-7.

What is Denosumab (usan) (615258-40-7) used for?

Denosumab, which was approved in the United States in 2010, is a fullyhuman sequence IgG2 monoclonal antibody that inhibits bone resorptionby blocking the activity of receptor activator of nuclear factor-κB ligand(RANKL). RANKL is a TNF family protein that is expressed in bothsecreted and cell surface forms by a variety of bone marrow cell typesandmediates bone resorption through its receptor (RANK),which is foundon osteoclasts and osteoclast precursors . Denosumab was discoveredusing XenomouseTM transgenic mice comprising human immunoglobulingenes. The antibody is approved for treatment of postmenopausalwomen with osteoporosis at high risk for fracture, and for the prevention ofskeletal-related events in patients with bone metastases from solid tumors.Denosumab competes directly with bisphosphonates such as alendronicacid in postmenopausal osteoporosis and with zoledronic acid in both ofthese indications. It has been shown to have comparable efficacy and safetyto bisphosphonates with some tolerability and patient acceptability advantages.

Product Class

615258-40-7

Product Name：Denosumab
Molecular Formula：C6404H9912N1724O2004S50
Purity：99%
Molecular Weight：144716.86

Inquiry

Product Details:

CasNo： 615258-40-7

Molecular Formula： C6404H9912N1724O2004S50

Chinese Manufacturer Supply 99% Pure Denosumab 615258-40-7 Competitive Price

Molecular Formula:C6404H9912N1724O2004S50
Molecular Weight:144716.86
PSA：0.00000
LogP:0.00000

Denosumab(Cas 615258-40-7) Usage

Description	Denosumab is a monoclonal antibody, a type of protein that is designed to mimic the immune system's ability to fight off harmful pathogens. It specifically targets a protein known as RANKL (Receptor Activator of Nuclear Factor κ B Ligand), which plays a role in bone breakdown.
Indications	Denosumab injection is used for the treatment of osteoporosis in postmenopausal women and in men who are at an increased risk for fractures. It is also used to treat osteoporosis when other medications cannot be used or have not been effective. Additionally, denosumab is employed in the treatment of hypercalcemia (high levels of calcium in the blood) and bone-related issues in cancer patients, including those with bone metastases from breast, prostate, and other solid tumors, as well as in patients with multiple myeloma.
Chemotherapy Status	Denosumab is not considered chemotherapy. It is a targeted therapy that specifically addresses bone-related issues by inhibiting RANKL. Chemotherapy typically involves the use of drugs that kill rapidly dividing cells, and denosumab functions differently by targeting a specific pathway involved in bone regulation.

615258-40-7 Relevant articles

Denosumab and bisphosphonates: Different mechanisms of action and effects

Roland Baron a b 1, Serge Ferrari c 1, R. Graham G. Russell d e 1

Bone Volume 48, Issue 4, 1 April 2011, Pages 677-692

In this review, we suggest that the key pharmacological differences between denosumab and the bisphosphonates reside in the distribution of the drugs within bone and their effects on precursors and mature osteoclasts. This may explain differences in the degree and rapidity of reduction of bone resorption, their potential differential effects on trabecular and cortical bone, and the reversibility of their actions.

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

List of authors. Steven R. Cummings, M.D., Javier San Martin, M.D., Michael R. McClung, M.D., Ethel S. Siris, M.D., Richard Eastell, M.D., Ian R. Reid, M.D., Pierre Delmas, M.D., Ph.D., Holly B. Zoog, Ph.D., Matt Austin, M.S., Andrea Wang, M.A., Stepan Kutilek, M.D., Silvano Adami, M.D., Ph.D., et al., for the FREEDOM Trial*

N Engl J Med 2009; 361:756-765

Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures.

Relevant Products

Sparsentan
CAS：254740-64-2
Etodolac
CAS：41340-25-4
LCZ696
CAS：936623-90-4